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February 2016 Abstracts S23non-malignant cells. Analysis of PCNA structure revealed
that the L126-Y133 region forms part of a pocket suit-
able for binding by a small molecule. We designed and
tested a series of small molecules that target this binding
pocket and identiﬁed AOH1160, a potent PCNA inhibitor,
which kills small cell lung cancer (SCLC) cells at high
nanomolar concentrations, but causes no signiﬁcant
toxicity to a broad range of non-malignant cells up to a
concentration of 10 mM. AOH1160 is orally available to
animals and inhibits tumor growth without causing any
observable side-effects, including weight loss, in mice.
These studies demonstrated the feasibility of inhibiting
the growth of SCLC cells by targeting a speciﬁc region of
PCNA without causing unacceptable toxicity to normal
tissues. Further development of AOH1160 may lead to a
novel anti-cancer therapy.Translational application of microRNA
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Background: Lung cancer has the highest mortality
rates of all the cancers in Canada with a 5 year survival
rate of less than 15%. Asymptomatic in its early stages,
methods to screen high risk individuals are in dire need
to allow earlier diagnosis and curative intent treatment.
MicroRNAs (miRNAs) are small, non-coding strands of
RNA that are shown to lead to carcinogenesis when
dysregulated. They are promising candidates for bio-
markers as they are stable, detectable in small quantities
and are expressed in a tissue speciﬁc manner. Through
the use of a miRNA panel developed by our group that
demonstrated good sensitivity and speciﬁcity using
sputum as a medium to measure miRNA., we aimed to
compare the efﬁcacy of measuring miRNA in sputum and
blood to develop a miRNA proﬁle for non-small cell lung
cancer (NSCLC).
Objective: To examine miRNA proﬁles of NSCLC cases
versus healthy controls to compare the efﬁcacy of
sputum and blood for potential screening purposes us-
ing microarray analysis.
Methods: A case control study of stage I/II cancers,
matched with controls having similar smoking history,
age, and gender, was performed. Participants were
recruited at the Royal Alexandra Hospital in Edmon-
ton, Alberta, Canada. Both sputum and blood arecollected and analyzed via Qiagen miRNA kits. 10
cases and 10 controls miRNA samples were submitted
for microarray analysis. miRNAs were labelled, hy-
bridized, and quantiﬁed using single-color experi-
mental design. Speciﬁc miRNAs from past literature
were then compared in cases and controls using Mann
Whitney U test.
Results: Sputum does not have consistent levels of
miRNA present when compared to blood, and principle
component analysis (PCA) plots show more random
patterns in sputum when compared to blood. By using
heat maps and hierarchical clustering, no apparent
clusters are seen when compared cases and controls in
both sputum and blood. A type II error could be
responsible for this ﬁnding due to the small sample size.
In an independent analysis looking at speciﬁc miRNAs
seen to be dysregulated in past literature, miR-147a is
signiﬁcantly different in sputum, and miR-126-5p is
signiﬁcantly different in blood.
Conclusions: Microarray analysis shows that sputum
is less consistent when measuring miRNAs compared
to blood overall. These ﬁndings have already been
applied to the next phase of our research which will
examine miRNA levels in high risk individuals as a
means of establishing it as a robust screening test for
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Clinical trials with single agent immune checkpoint in-
hibitors, mainly the anti-PD-1 antibody, have achieved
noteworthy beneﬁt with an objective response rate in
17% of non-small cell lung cancer (NSCLC) patients.
However, minimal or no response in a large proportion
of patients suggest that additional immune suppression
pathways need to be identiﬁed in the tumor microenvi-
ronment to deﬁne combination immune therapies for
future therapeutic intervention. We have focused our
studies on the KRAS mutant subset, as it accounts for
>30% of NSCLC patients with high mortality rates due
to a conspicuous lack of effective FDA approved targeted
therapies.
To enable selection of appropriate immunother-
apies, we have performed comprehensive analysis of
immune microenvironments in a mouse model of
